Suppliers and packagers for tecfidera

tecfidera

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063	NDA	Biogen Inc.	64406-005-01	1 BOTTLE, PLASTIC in 1 CARTON (64406-005-01) / 14 CAPSULE in 1 BOTTLE, PLASTIC	2013-03-27
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063	NDA	Biogen Inc.	64406-006-02	1 BOTTLE, PLASTIC in 1 CARTON (64406-006-02) / 60 CAPSULE in 1 BOTTLE, PLASTIC	2013-03-27
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063	NDA	Biogen Inc.	64406-007-03	1 KIT in 1 KIT (64406-007-03) * 14 CAPSULE in 1 BOTTLE, PLASTIC * 46 CAPSULE in 1 BOTTLE, PLASTIC	2013-03-27

TECFIDERA (DIMETHYL FUMARATE) SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report analyzes the global supply chain for Tecfidera (dimethyl fumarate), a prescription medication used to treat relapsing forms of multiple sclerosis. The analysis focuses on key suppliers of active pharmaceutical ingredients (APIs) and finished drug product manufacturing.

Who Manufactures Tecfidera's Active Pharmaceutical Ingredient?

The primary active pharmaceutical ingredient for Tecfidera is dimethyl fumarate. Key manufacturers of dimethyl fumarate API include:

• Huaian Ruiding Bio-chemical Co., Ltd. Based in China, this company is a significant producer of fumaric acid derivatives, including dimethyl fumarate. Their production capacity and quality control systems are critical to the global supply.

• Merck KGaA (Darmstadt, Germany) is the originator and primary manufacturer of Tecfidera. While they likely have internal manufacturing capabilities for dimethyl fumarate, they also engage third-party suppliers to ensure robust supply. Information on their specific internal API production scale or dedicated external API suppliers beyond general identification is proprietary.

• Jubilant Pharmova Limited (India) is a diversified pharmaceutical company with API manufacturing capabilities. While not explicitly listed as a primary Tecfidera API supplier in public domain documents, their broad API portfolio and established pharmaceutical supply chains suggest potential involvement as a secondary or backup supplier, contingent on contractual agreements.

The global production of dimethyl fumarate API is concentrated in regions with established chemical manufacturing infrastructure, particularly China and India. These regions offer cost efficiencies and large-scale production capabilities. Supplier qualification by Biogen, the marketing authorization holder for Tecfidera, involves rigorous audits to ensure compliance with Good Manufacturing Practices (GMP) and consistent product quality.

Where is Tecfidera Finished Drug Product Manufactured?

Biogen, the marketing authorization holder for Tecfidera, oversees the manufacturing of the finished drug product. This process involves formulating the dimethyl fumarate API into the final dosage form (capsules) and packaging. Manufacturing sites for Tecfidera finished drug product include:

• Biogen Facilities: Biogen operates its own manufacturing facilities and has historically produced key biologics and small molecules at sites such as its Research Triangle Park (RTP) facility in North Carolina, USA, and its facility in Solothurn, Switzerland. These sites are subject to stringent regulatory oversight by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Contract Manufacturing Organizations (CMOs): Biogen also leverages CMOs for drug product manufacturing and packaging. Identifying specific CMOs involved in Tecfidera production is challenging due to the confidential nature of these contractual relationships. However, common CMOs in the pharmaceutical industry that possess the capabilities for solid dosage form manufacturing and packaging include:

  • Catalent Pharma Solutions: A global provider of drug delivery technologies and manufacturing services.
  • Thermo Fisher Scientific: Offers a broad range of pharmaceutical services, including contract development and manufacturing.
  • Lonza Group: A Swiss multinational and a leading supplier to the pharmaceutical, biotech, and nutrition markets.

The selection of CMOs is based on their adherence to regulatory standards (e.g., FDA, EMA), their technological capabilities for precise encapsulation and packaging, and their capacity to meet Biogen's production volumes and quality requirements. Supply chain resilience is often built through dual sourcing strategies, involving multiple CMOs or a combination of internal and external manufacturing.

What Are the Key Regulatory Considerations for Tecfidera's Supply Chain?

The pharmaceutical supply chain for Tecfidera is subject to extensive regulatory oversight to ensure product safety, efficacy, and quality. Key regulatory considerations include:

• Good Manufacturing Practices (GMP): All manufacturing facilities involved in API production, drug product formulation, and packaging must adhere to stringent GMP guidelines. These are enforced by regulatory bodies such as the FDA (21 CFR Parts 210 and 211) and the EMA. GMP compliance ensures that products are consistently produced and controlled according to quality standards.

• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. Biogen references these DMFs in its drug applications, allowing regulatory bodies to review the API's manufacturing information without disclosing proprietary details to Biogen.

• Supply Chain Security and Traceability: Regulations like the U.S. Drug Supply Chain Security Act (DSCSA) and the EU Falsified Medicines Directive (FMD) mandate robust systems for product tracing and serialization. This involves assigning unique serial numbers to drug packages to track them throughout the supply chain and prevent counterfeit products from entering the market.

• Quality Agreements: Biogen establishes detailed quality agreements with its API suppliers and CMOs. These agreements define responsibilities related to quality control, change management, deviation handling, recalls, and audits, ensuring that all parties meet agreed-upon quality standards.

• Environmental, Social, and Governance (ESG) Standards: Increasingly, pharmaceutical companies are scrutinizing their suppliers for compliance with ESG standards, including labor practices, environmental impact, and ethical sourcing. Regulatory bodies and investors are placing greater emphasis on sustainable and responsible supply chain management.

How Does Supply Chain Resilience Impact Tecfidera Availability?

Supply chain resilience is paramount for ensuring the continuous availability of Tecfidera to patients. Disruptions can arise from various factors:

• Geopolitical Instability: Sourcing API from regions prone to political unrest or trade disputes can create significant risks. For example, reliance on a single supplier in a politically unstable region could lead to manufacturing stoppages.

• Natural Disasters: Earthquakes, floods, or pandemics can impact manufacturing operations and logistics, affecting the availability of raw materials or finished products. The COVID-19 pandemic highlighted vulnerabilities in global supply chains, leading to increased inventory holding and diversification of sourcing strategies.

• Regulatory Actions: FDA or EMA inspections that result in manufacturing site shutdowns or product recalls can lead to temporary or prolonged supply shortages. Adherence to evolving regulatory requirements is critical.

• Supplier Financial Health: The financial stability of key suppliers is crucial. A supplier facing bankruptcy or significant financial distress could jeopardize the supply of critical components.

• Logistical Challenges: Transportation disruptions, port congestion, or increased shipping costs can delay the movement of materials and finished goods, impacting delivery timelines.

To mitigate these risks, Biogen employs strategies such as:

• Dual Sourcing: Qualifying and utilizing multiple suppliers for critical raw materials and contract manufacturing services reduces reliance on a single source. This provides redundancy in case of supplier issues.

• Inventory Management: Maintaining appropriate levels of safety stock for APIs and finished products can buffer against short-term supply interruptions.

• Geographic Diversification: Spreading manufacturing and sourcing across different geographic regions can reduce the impact of localized disruptions.

• Supplier Relationship Management: Building strong relationships with key suppliers through transparent communication and collaborative problem-solving enhances supply chain reliability.

• Supply Chain Visibility Tools: Implementing technology that provides real-time tracking of materials and products across the supply chain enables proactive identification and management of potential disruptions.

What Are the Current Market Dynamics Affecting Tecfidera's Supply?

The market for Tecfidera is influenced by several dynamics:

• Patent Expirations and Generic Competition: Tecfidera's primary patents have been or are nearing expiration in major markets. This opens the door for generic manufacturers to enter the market. The emergence of generic dimethyl fumarate products can lead to increased demand for API from multiple sources and potential price pressures, impacting the sourcing strategies of both Biogen and generic manufacturers.

• Demand Fluctuations: The prevalence and diagnosis rates of relapsing forms of multiple sclerosis, coupled with physician prescribing habits and patient access to treatment, influence the demand for Tecfidera. Unforeseen increases in demand can strain existing supply chains.

• Advancements in MS Therapies: The development of new and potentially more effective or convenient treatments for multiple sclerosis can affect the market share of Tecfidera, indirectly impacting production volumes and supply chain planning.

• Cost Pressures: Both Biogen and generic manufacturers face pressure to optimize manufacturing costs. This can lead to a greater emphasis on cost-competitive sourcing of APIs and contract manufacturing services, particularly from emerging markets.

• Regulatory Scrutiny on Supply Chains: Increased global attention on pharmaceutical supply chain integrity, quality, and sustainability means that manufacturers must continuously adapt to evolving regulatory expectations and demonstrate robust compliance.

Key Takeaways

• The supply chain for Tecfidera (dimethyl fumarate) involves global API manufacturers, primarily based in China and India, and finished drug product manufacturing, utilizing Biogen's internal facilities and contract manufacturing organizations.
• Regulatory compliance, including GMP, DMF submissions, and supply chain security, is a critical component of Tecfidera's manufacturing and distribution.
• Supply chain resilience is actively managed through dual sourcing, geographic diversification, and robust inventory strategies to mitigate risks from geopolitical events, natural disasters, and regulatory actions.
• Market dynamics, including impending patent expirations leading to generic competition, demand fluctuations, and the introduction of new MS therapies, significantly influence Tecfidera's supply chain operations and sourcing decisions.

Frequently Asked Questions

1. Who is the primary API supplier for Tecfidera?

While Biogen, the originator, has internal capabilities, Huaian Ruiding Bio-chemical Co., Ltd. is a noted significant producer of dimethyl fumarate API globally. Specific contractual relationships are proprietary.

2. Are there any known single points of failure in Tecfidera's supply chain?

Publicly available information does not definitively identify single points of failure. However, reliance on any single supplier for a critical component, whether API or a specific CMO, inherently introduces risk. Biogen's strategy likely includes qualifying multiple suppliers to mitigate this.

3. What is the typical lead time for securing a new API supplier for a drug like Tecfidera?

The qualification and approval process for a new API supplier can take 12 to 18 months, sometimes longer. This involves rigorous auditing, quality assessments, and regulatory filings to ensure the supplier meets all necessary standards and that the API is interchangeable.

4. How does Biogen manage quality control across its global Tecfidera supply chain?

Biogen manages quality through comprehensive quality agreements with all suppliers and contract manufacturers. These agreements detail responsibilities for quality control testing, change management, deviation investigations, and joint audits to ensure consistent adherence to GMP.

5. What impact will generic Tecfidera products have on the existing API supply chain?

The introduction of generic dimethyl fumarate products is expected to increase demand for the API, potentially leading to greater competition among API suppliers and increased sourcing activity. Biogen's existing supply chain may need to adapt to price pressures and potential shifts in market share.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-compliance/current-good-manufacturing-practice-cgmp-regulations [2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/compliance-research-and-development/good-manufacturing-practice-gmp [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files [4] U.S. Food and Drug Administration. (n.d.). Drug Supply Chain Security Act (DSCSA). Retrieved from https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa [5] European Commission. (n.d.). Falsified medicines. Retrieved from https://health.ec.europa.eu/medicinal-products/falsified-medicines_en